Compare BFC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | IMCR |
|---|---|---|
| Founded | 1894 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 2016 |
| Metric | BFC | IMCR |
|---|---|---|
| Price | $136.37 | $33.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $150.00 | $64.70 |
| AVG Volume (30 Days) | 75.9K | ★ 379.9K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | 11.23 | ★ 30.39 |
| EPS | ★ 7.23 | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $58.67 | $14.39 |
| Revenue Next Year | $2.01 | $8.19 |
| P/E Ratio | $18.87 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $93.00 | $23.15 |
| 52 Week High | $153.00 | $40.71 |
| Indicator | BFC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 50.92 |
| Support Level | $118.71 | $31.21 |
| Resistance Level | $140.92 | $34.86 |
| Average True Range (ATR) | 4.21 | 1.72 |
| MACD | -1.20 | 0.10 |
| Stochastic Oscillator | 28.64 | 57.18 |
Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.